TET1 exerts its tumor suppressor function by interacting with p53-EZH2 pathway in gastric cancer

Journal of Biomedical Nanotechnology

Volumn 10, Issue 7, 2014, Pages 1217-1230

  Fu, Hua Lin ^a   Ma, Yue ^a   Lu, Lun Gen ^b   Hou, Peng ^c   Li, Bao Jie ^a   Jin, Wei Lin ^a   Cui, Da Xiang ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b SHANGHAI FIRST PEOPLE S HOSPITAL   (China)

^c XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

5 Hydroxymethyl Cytosine; DNA PK; EZH2; P53; TET1

Indexed keywords

CELL CULTURE; CELL PROLIFERATION; CELLS; DNA; PROTEINS; TUMORS;

5-HYDROXYMETHYL-CYTOSINE; DNA-PK; EZH2; P53; TET1;

DISEASES;

5 HYDROXYMETHYLCYTOSINE; KI 67 ANTIGEN; ONCOPROTEIN; PROTEIN P53; TET1 PROTEIN; TET2 PROTEIN; TRANSCRIPTION FACTOR EZH2; UNCLASSIFIED DRUG; 5-HYDROXYMETHYLCYTOSINE; CYTOSINE; DNA BINDING PROTEIN; DNA DEPENDENT PROTEIN KINASE; EZH2 PROTEIN, HUMAN; NUCLEAR PROTEIN; PHOSPHOSERINE; POLYCOMB REPRESSIVE COMPLEX 2; PRKDC PROTEIN, HUMAN; PROTEIN BINDING; TET1 PROTEIN, HUMAN; TET2 PROTEIN, HUMAN; TUMOR MARKER;

ARTICLE; CANCER CELL CULTURE; CELL POPULATION; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; MALE; METHYLATION; ONCOGENE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; STOMACH CANCER; STOMACH EPITHELIUM; STOMACH MUCOSA; UPREGULATION; ANALOGS AND DERIVATIVES; ANIMAL; METABOLISM; MOUSE; PATHOLOGY; PHOSPHORYLATION; SIGNAL TRANSDUCTION; STOMACH TUMOR; TISSUE MICROARRAY; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; CYTOSINE; DNA-ACTIVATED PROTEIN KINASE; DNA-BINDING PROTEINS; DOWN-REGULATION; GASTRIC MUCOSA; HUMANS; KI-67 ANTIGEN; MICE; NUCLEAR PROTEINS; PHOSPHORYLATION; PHOSPHOSERINE; POLYCOMB REPRESSIVE COMPLEX 2; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 84899080677     PISSN: 15507033     EISSN: 15507041     Source Type: Journal    
DOI: 10.1166/jbn.2014.1861     Document Type: Article

References (78)

1. P. Hohenberger and S. Gretschel, Gastric cancer. Lancet 362, 305 (2003).
2. K. D. Crew and A. I. Neugut, Epidemiology of gastric cancer. World J. Gastroenterol. 12, 354 (2006).
3. M. Dobbelstein and J. Roth, The large T antigen of simian virus 40 binds and inactivates p53 but not p73. J. Gen. Virol. 79, 3079 (1998).
4. D. Eliyahu, D. Michalovitz, S. Eliyahu, O. Pinhasi-Kimhi, and M. Oren, Wild-type p53 can inhibit oncogene-mediated focus formation. Proc. Natl. Acad. Sci. USA 86, 8763 (1989).
5. H. Lee, S. O. Yoon, W. Y. Jeong, H. K. Kim, A. Kim, and B. H. Kim, Immunohistochemical analysis of polycomb group protein expression in advanced gastric cancer. Hum. Pathol. 43, 1704 (2012).
6. J. H. Choi, Y. S. Song, J. S. Yoon, K. W. Song, and Y. Y. Lee, Enhancer of zeste homolog 2 expression is associated with tumor cell proliferation and metastasis in gastric cancer. Apmis 118, 196 (2010).
7. G. H. Cai, K. Wang, Q. Miao, Y. S. Peng, and X. Y. Chen, Expression of polycomb protein EZH2 in multi-stage tissues of gastric carcinogenesis. J. Dig. Dis. 11, 88 (2010).
8. Y. Matsukawa, S. Semba, H. Kato, A. Ito, K. Yanagihara, and H. Yokozaki, Expression of the enhancer of zeste homolog 2 is correlated with poor prognosis in human gastric cancer. Cancer Sci. 97, 484 (2006).
9. H. P. Visser, M. J. Gunster, H. C. Kluin-Nelemans, E. M. Manders, F. M. Raaphorst, C. J. Meijer, R. Willemze, and A. P. Otte, The polycomb group protein EZH2 is up-regulated in proliferating, cultured human mantle cell lymphoma. Br. J. Haematol. 112, 950 (2001).
10. F. J. van Kemenade, F. M. Raaphorst, T. Blokzijl, E. Fieret, K. M. Hamer, D. P. Satijn, A. P. Otte, and C. J. Meijer, Coexpression of BMI-1 and EZH2 polycomb-group proteins is associated with cycling cells and degree of malignancy in B-cell non-Hodgkin lymphoma. Blood 97, 3896 (2001).
11. S. Varambally, S. M. Dhanasekaran, M. Zhou, T. R. Barrette, C. Kumar-Sinha, M. G. Sanda, D. Ghosh, K. J. Pienta, R. G. Sewalt, A. P. Otte, M. A. Rubin, and A. M. Chinnaiyan, The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419, 624 (2002).
12. C. G. Kleer, Q. Cao, S. Varambally, R. Shen, I. Ota, S. A. Tomlins, D. Ghosh, R. G. Sewalt, A. P. Otte, D. F. Hayes, M. S. Sabel, D. Livant, S. J. Weiss, M. A. Rubin, and A. M. Chinnaiyan, EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc. Natl. Acad. Sci. USA 100, 11606 (2003).
13. X. Li, M. E. Gonzalez, K. Toy, T. Filzen, S. D. Merajver, and C. G. Kleer, Targeted overexpression of EZH2 in the mammary gland disrupts ductal morphogenesis and causes epithelial hyperplasia. Am. J. Pathol. 175, 1246 (2009).
14. S. Weikert, F. Christoph, J. Kollermann, M. Muller, M. Schrader, K. Miller, and H. Krause, Expression levels of the EZH2 polycomb transcriptional repressor correlate with aggressiveness and invasive potential of bladder carcinomas. Int. J. Mol. Med. 16, 349 (2005).
15. B. Czermin, R. Melfi, D. McCabe, V. Seitz, A. Imhof, and V. Pirrotta, Drosophila enhancer of zeste/ESC complexes have a histone H3 methyltransferase activity that marks chromosomal polycomb sites. Cell 111, 185 (2002).
16. D. O'Carroll, S. Erhardt, M. Pagani, S. C. Barton, M. A. Surani, and T. Jenuwein, The polycomb-group gene Ezh2 is required for early mouse development. Mol. Cell Biol. 21, 4330 (2001).
17. A. P. Bracken, D. Pasini, M. Capra, E. Prosperini, E. Colli, and K. Helin, EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. Embo J. 22, 5323 (2003).
18. M. Sasaki, J. Yamaguchi, K. Itatsu, H. Ikeda, and Y. Nakanuma, Over-expression of polycomb group protein EZH2 relates to decreased expression of p16 INK4a in cholangiocarcinogenesis in hepatolithiasis. J. Pathol. 215, 175 (2008).
19. H. Chen, X. Gu, I. H. Su, R. Bottino, J. L. Contreras, A. Tarakhovsky, and S. K. Kim, Polycomb protein Ezh2 regulates pancreatic beta-cell Ink4a/Arf expression and regeneration in diabetes mellitus. Genes Dev. 23, 975 (2009).
20. X. Tang, M. Milyavsky, I. Shats, N. Erez, N. Goldfinger, and V. Rotter, Activated p53 suppresses the histone methyltransferase EZH2 gene. Oncogene 23, 5759 (2004).
21. E. Mattioli, P. Vogiatzi, A. Sun, G. Abbadessa, G. Angeloni, D. D'Ugo, D. Trani, J. P. Gaughan, F. M. Vecchio, G. Cevenini, R. Persiani, A. Giordano, and P. P. Claudio, Immunohistochemical analysis of pRb2/p130, VEGF, EZH2, p53, p16(INK4A), p27(KIP1), p21(WAF1), Ki-67 expression patterns in gastric cancer. J. Cell Physiol. 210, 183 (2007).
22. Y. Kudo, K. Tateishi, K. Yamamoto, S. Yamamoto, Y. Asaoka, H. Ijichi, G. Nagae, H. Yoshida, H. Aburatani, and K. Koike, Loss of 5-hydroxymethylcytosine is accompanied with malignant cellular transformation. Cancer Sci. 103, 670 (2012).
23. C. H. Hsu, K. L. Peng, M. L. Kang, Y. R. Chen, Y. C. Yang, C. H. Tsai, C. S. Chu, Y. M. Jeng, Y. T. Chen, F. M. Lin, H. D. Huang, Y. Y. Lu, Y. C. Teng, S. T. Lin, R. K. Lin, F. M. Tang, S. B. Lee, H. M. Hsu, J. C. Yu, P. W. Hsiao, and L. J. Juan, TET1 suppresses cancer invasion by activating the tissue inhibitors of metalloproteinases. Cell Rep. 2, 568 (2012).
24. H. Yang, Y. Liu, F. Bai, J. Y. Zhang, S. H. Ma, J. Liu, Z. D. Xu, H. G. Zhu, Z. Q. Ling, D. Ye, K. L. Guan, and Y. Xiong, Tumor development is associated with decrease of TET gene expression and 5-methylcytosine hydroxylation. Oncogene 32, 663 (2012).
25. M. C. Haffner, A. Chaux, A. K. Meeker, D. M. Esopi, J. Gerber, L. G. Pellakuru, A. Toubaji, P. Argani, C. Iacobuzio-Donahue, W. G. Nelson, G. J. Netto, A. M. De Marzo, and S. Yegnasubramanian, Global 5-hydroxymethylcytosine content is significantly reduced in tissue stem/progenitor cell compartments and in human cancers. Oncotarget 2, 627 (2011).
26. C. G. Lian, Y. Xu, C. Ceol, F. Wu, A. Larson, K. Dresser, W. Xu, L. Tan, Y. Hu, Q. Zhan, C. W. Lee, D. Hu, B. Q. Lian, S. Kleffel, Y. Yang, J. Neiswender, A. J. Khorasani, R. Fang, C. Lezcano, L. M. Duncan, R. A. Scolyer, J. F. Thompson, H. Kakavand, Y. Houvras, L. I. Zon, M. C. Mihm Jr, U. B. Kaiser, T. Schatton, B. A. Woda, G. F. Murphy, and Y. G. Shi, Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanoma. Cell 150, 1135 (2012).
27. S. Ito, A. C. D'Alessio, O. V. Taranova, K. Hong, L. C. Sowers, and Y. Zhang, Role of Tet proteins in 5mC to 5-hmc conversion, ES-cell self-renewal and inner cell mass specification. Nature 466, 1129 (2010).
28. S. Ito, L. Shen, Q. Dai, S. C. Wu, L. B. Collins, J. A. Swenberg, C. He, and Y. Zhang, Tet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine. Science 333, 1300 (2011).
29. Y. F. He, B. Z. Li, Z. Li, P. Liu, Y. Wang, Q. Tang, J. Ding, Y. Jia, Z. Chen, L. Li, Y. Sun, X. Li, Q. Dai, C. X. Song, K. Zhang, C. He, and G. L. Xu, Tet-mediated formation of 5-carboxylcytosine and its excision by TDG in mammalian DNA. Science 333, 1303 (2011).
30. Q. Yang, K. Wu, M. Ji, W. Jin, N. He, B. Shi, and P. Hou, Decreased 5-hydroxymethylcytosine (5-hmC) is an independent poor prognostic factor in gastric cancer patients. J. Biomed. Nanotechnol. 9, 1607 (2013).
31. R. B. Lorsbach, J. Moore, S. Mathew, S. C. Raimondi, S. T. Mukatira, and J. R. Downing, TET1, a member of a novel protein family, is fused to MLL in acute myeloid leukemia containing the t(10; 11)(q22; q23). Leukemia 17, 637 (2003).
32. M. Ko, Y. Huang, A. M. Jankowska, U. J. Pape, M. Tahiliani, H. S. Bandukwala, J. An, E. D. Lamperti, K. P. Koh, R. Ganetzky, X. S. Liu, L. Aravind, S. Agarwal, J. P. Maciejewski, and A. Rao, Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature 468, 839 (2010).
33. M. Sun, C. X. Song, H. Huang, C. A. Frankenberger, D. Sankarasharma, S. Gomes, P. Chen, J. Chen, K. K. Chada, C. He, and M. R. Rosner, HMGA2/TET1/HOXA9 signaling pathway regulates breast cancer growth and metastasis. Proc. Natl. Acad. Sci. USA 110, 9920 (2013).
34. C. Liu, L. Liu, X. Chen, J. Shen, J. Shan, Y. Xu, Z. Yang, L. Wu, F. Xia, P. Bie, Y. Cui, X. W. Bian, and C. Qian, Decrease of 5-hydroxymethylcytosine is associated with progression of hepatocellular carcinoma through down-regulation of TET1. PLoS One 8, e62828 (2013).
35. H. Wu, A. C. D'Alessio, S. Ito, K. Xia, Z. Wang, K. Cui, K. Zhao, Y. E. Sun, and Y. Zhang, Dual functions of Tet1 in transcriptional regulation in mouse embryonic stem cells. Nature 473, 389 (2011).
36. H. Wu, A. C. D'Alessio, S. Ito, Z. Wang, K. Cui, K. Zhao, Y. E. Sun, and Y. Zhang, Genome-wide analysis of 5-hydroxymethylcytosine distribution reveals its dual function in transcriptional regulation in mouse embryonic stem cells. Genes Dev. 25, 679 (2011).
37. W. A. Pastor, U. J. Pape, Y. Huang, H. R. Henderson, R. Lister, M. Ko, E. M. McLoughlin, Y. Brudno, S. Mahapatra, P. Kapranov, M. Tahiliani, G. Q. Daley, X. S. Liu, J. R. Ecker, P. M. Milos, S. Agarwal, and A. Rao, Genome-wide mapping of 5-hydroxymethylcytosine in embryonic stem cells. Nature 473, 394 (2011).
38. K. Chen, Y. J. Mi, Y. Ma, H. L. Fu, and W. L. Jin, The mental retardation associated protein, srGAP3 negatively regulates VPA-induced neuronal differentiation of Neuro2A cells. Cell Mol. Neurobiol. 31, 675 (2011).
39. T. Muller, M. Gessi, A. Waha, L. J. Isselstein, D. Luxen, D. Freihoff, J. Freihoff, A. Becker, M. Simon, J. Hammes, D. Denkhaus, A. Zur Muhlen, and T. Pietsch, Nuclear exclusion of TET1 is associated with loss of 5-hydroxymethylcytosine in IDH1 wild-type gliomas. Am. J. Pathol. 181, 675 (2012).
40. C. Frauer, A. Rottach, D. Meilinger, S. Bultmann, K. Fellinger, S. Hasenoder, M. Wang, W. Qin, J. Soding, F. Spada, and H. Leonhardt, Different binding properties and function of CXXC zinc finger domains in Dnmt1 and Tet1. PLoS One 6, e16627 (2011).
41. J. H. van Dierendonck, R. Keijzer, C. J. van de Velde, and C. J. Cornelisse, Nuclear distribution of the Ki-67 antigen during the cell cycle: Comparison with growth fraction in human breast cancer cells. Cancer Res. 49, 2999 (1989).
42. M. Chmelarova, E. Krepinska, J. Spacek, J. Laco, M. Beranek, and V. Palicka, Methylation in the p53 promoter in epithelial ovarian cancer. Clin. Transl. Oncol. 15, 160 (2012).
43. R. Radpour, Z. Barekati, M. M. Haghighi, C. Kohler, R. Asadollahi, P. M. Torbati, W. Holzgreve, and X. Y. Zhong, Correlation of telomere length shortening with promoter methylation profile of p16/Rb and p53/p21 pathways in breast cancer. Mod. Pathol. 23, 763 (2010).
44. I. P. Pogribny and S. J. James, Reduction of p53 gene expression in human primary hepatocellular carcinoma is associated with promoter region methylation without coding region mutation. Cancer Lett. 176, 169 (2002).
45. J. A. Rusiecki, M. Al-Nabhani, L. Tarantini, L. Chen, A. Baccarelli, and M. S. Al-Moundhri, Global DNA methylation and tumor suppressor gene promoter methylation and gastric cancer risk in an Omani Arab population. Epigenomics 3, 417 (2011).
46. C. P. Rubbi and J. Milner, p53 is a chromatin accessibility factor for nucleotide excision repair of DNA damage. Embo J. 22, 975 (2003).
47. R. Carbone, M. Pearson, S. Minucci, and P. G. Pelicci, PML NBs associate with the hMre11 complex and p53 at sites of irradiation induced DNA damage. Oncogene 21, 1633 (2002).
48. S. Cortellino, J. Xu, M. Sannai, R. Moore, E. Caretti, A. Cigliano, M. Le Coz, K. Devarajan, A. Wessels, D. Soprano, L. K. Abramowitz, M. S. Bartolomei, F. Rambow, M. R. Bassi, T. Bruno, M. Fanciulli, C. Renner, A. J. Klein-Szanto, Y. Matsumoto, D. Kobi, I. Davidson, C. Alberti, L. Larue, and A. Bellacosa, Thymine DNA glycosylase is essential for active DNA demethylation by linked deamination-base excision repair. Cell 146, 67 (2011).
49. A. Maiti and A. C. Drohat, Thymine DNA glycosylase can rapidly excise 5-formylcytosine and 5-carboxylcytosine: Potential implications for active demethylation of CpG sites. J. Biol. Chem. 286, 35334 (2011).
50. Y. Haupt, R. Maya, A. Kazaz, and M. Oren, Mdm2 promotes the rapid degradation of p53. Nature 387, 296 (1997).
51. H. Zhao, F. Traganos, and Z. Darzynkiewicz, Phosphorylation of p53 on Ser15 during cell cycle caused by Topo I and Topo II inhibitors in relation to ATM and Chk2 activation. Cell Cycle 7, 3048 (2008).
52. R. S. Tibbetts, K. M. Brumbaugh, J. M. Williams, J. N. Sarkaria, W. A. Cliby, S. Y. Shieh, Y. Taya, C. Prives, and R. T. Abraham, A role for ATR in the DNA damage-induced phosphorylation of p53. Genes Dev. 13, 152 (1999).
53. G. Achanta, H. Pelicano, L. Feng, W. Plunkett, and P. Huang, Interaction of p53 and DNA-PK in response to nucleoside analogues: Potential role as a sensor complex for DNA damage. Cancer Res. 61, 8723 (2001).
54. M. A. Serrano, Z. Li, M. Dangeti, P. R. Musich, S. Patrick, M. Roginskaya, B. Cartwright, and Y. Zou, DNA-PK, ATM and ATR collaboratively regulate p53-RPA interaction to facilitate homologous recombination DNA repair. Oncogene 32, 2452 (2013).
55. K. Yoshida, T. Ozaki, K. Furuya, M. Nakanishi, H. Kikuchi, H. Yamamoto, S. Ono, T. Koda, K. Omura, and A. Nakagawara, ATM-dependent nuclear accumulation of IKK-alpha plays an important role in the regulation of p73-mediated apoptosis in response to cisplatin. Oncogene 27, 1183 (2008).
56. D. Vauzour, K. Vafeiadou, C. Rice-Evans, E. Cadenas, and J. P. Spencer, Inhibition of cellular proliferation by the genistein metabolite 5,7,3′,4′-tetrahydroxyisoflavone is mediated by DNA damage and activation of the ATR signalling pathway. Arch. Biochem. Biophys. 468, 159 (2007).
57. B. P. Chen, D. W. Chan, J. Kobayashi, S. Burma, A. Asaithamby, K. Morotomi-Yano, E. Botvinick, J. Qin, and D. J. Chen, Cell cycle dependence of DNA-dependent protein kinase phosphorylation in response to DNA double strand breaks. J. Biol. Chem. 280, 14709 (2005).
58. M. M. Vilenchik and A. G. Knudson, Jr, Inverse radiation dose-rate effects on somatic and germ-line mutations and DNA damage rates. Proc. Natl. Acad. Sci. USA 97, 5381 (2000).
59. Z. Ali, Y. Deng, Y. Tang, S. Zheng, N. Ma, and N. He, Epigenetic deregulations in gastric cancer. J. Nanosci. Nanotechnol. 13, 40 (2013).
60. Z. Ali, Y. Deng, and C. Ma, Progress of research in gastric cancer. J. Nanosci. Nanotechnol. 12, 8241 (2012).
61. D. Ziogas and D. Roukos, Epigenetics in gastric cancer: Challenges for clinical implications. Ann. Surg. Oncol. 16, 2077 (2009).
62. R. R. Zhang, Q. Y. Cui, K. Murai, Y. C. Lim, Z. D. Smith, S. Jin, P. Ye, L. Rosa, Y. K. Lee, H. P. Wu, W. Liu, Z. M. Xu, L. Yang, Y. Q. Ding, F. Tang, A. Meissner, C. Ding, Y. Shi, and G. L. Xu, Tet1 regulates adult hippocampal neurogenesis and cognition. Cell Stem Cell 13, 237 (2013).
63. Q. Chen, Y. Chen, C. Bian, R. Fujiki, and X. Yu, TET2 promotes histone O-GlcNAcylation during gene transcription. Nature 493, 561 (2013).
64. D. L. Rimm, K. Caca, G. Hu, F. B. Harrison, and E. R. Fearon, Frequent nuclear/cytoplasmic localization of beta-catenin without exon 3 mutations in malignant melanoma. Am. J. Pathol. 154, 325 (1999).
65. R. G. Bedolla, Y. Wang, A. Asuncion, K. Chamie, S. Siddiqui, M. M. Mudryj, T. J. Prihoda, J. Siddiqui, A. M. Chinnaiyan, R. Mehra, R. W. de Vere White, and P. M. Ghosh, Nuclear versus cytoplasmic localization of filamin A in prostate cancer: Immunohistochemical correlation with metastases. Clin. Cancer Res. 15, 788 (2009).
66. B. V. McConnell, K. Koto, and A. Gutierrez-Hartmann, Nuclear and cytoplasmic LIMK1 enhances human breast cancer progression. Mol. Cancer 10, 75 (2011).
67. Y. Arioka, A. Watanabe, K. Saito, and Y. Yamada, Activation-induced cytidine deaminase alters the subcellular localization of Tet family proteins. PLoS One 7, e45031 (2012).
68. G. A. Kaas, C. Zhong, D. E. Eason, D. L. Ross, R. V. Vachhani, G. L. Ming, J. R. King, H. Song, and J. D. Sweatt, TET1 controls CNS 5-methylcytosine hydroxylation, active DNA demethylation, gene transcription, and memory formation. Neuron 79, 1086 (2013).
69. T. P. Gu, F. Guo, H. Yang, H. P. Wu, G. F. Xu, W. Liu, Z. G. Xie, L. Shi, X. He, S. G. Jin, K. Iqbal, Y. G. Shi, Z. Deng, P. E. Szabo, G. P. Pfeifer, J. Li, and G. L. Xu, The role of Tet3 DNA dioxygenase in epigenetic reprogramming by oocytes. Nature 477, 606 (2011).
70. L. A. Donehower, M. Harvey, B. L. Slagle, M. J. McArthur, C. A. Montgomery, Jr, J. S. Butel, and A. Bradley, Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356, 215 (1992).
71. A. Yang, M. Kaghad, Y. Wang, E. Gillett, M. D. Fleming, V. Dotsch, N. C. Andrews, D. Caput, and F. McKeon, p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol. Cell. 2, 305 (1998).
72. C. A. Jost, M. C. Marin, and W. G. Kaelin, Jr, p73 is a simian [correction of human] p53-related protein that can induce apoptosis. Nature 389, 191 (1997).
73. E. Parlanti, G. Locatelli, G. Maga, and E. Dogliotti, Human base excision repair complex is physically associated to DNA replication and cell cycle regulatory proteins. Nucleic Acids Res. 35, 1569 (2007).
74. P. C. Hanawalt and G. Spivak, Transcription-coupled DNA repair: Two decades of progress and surprises. Nat. Rev. Mol. Cell Biol. 9, 958 (2008).
75. A. Neves-Costa and L. F. Moita, TET1 is a negative transcriptional regulator of IL-1beta in the THP-1 cell line. Mol. Immunol. 54, 264 (2013).
76. J. Chen, W. Wang, T. Zhang, J. Ji, Q. Qian, L. Lu, H. Fu, W. Jin, and D. Cui, Differential expression of phospholipase C epsilon 1 is associated with chronic atrophic gastritis and gastric cancer. PLoS One 7, e47563 (2012).
77. J. R. Xu, L. Zhang, L. X. Zhang, K. Wang, J. Chen, C. H. Jia, L. L. Feng, and D. X. Cui, Gene expression profiles of rodent atrophic gastritis induced by hot and salt water. Nano Biomed. Eng. 3, 236 (2011).
78. D. X. Cui, L. Zhang, X. J. Yan, L. X. Zhang, J. R. Xu, Y. H. Guo, G. Q. Jin, G. Gomez, D. Li, J. R. Zhao, F. C. Han, J. Zhang, J. L. Hu, D. M. Fan, and H. J. Gao, A microarray-based gastric carcinoma prewarning system. World J. Gastroenterol. 11, 1273 (2005).